Almirall + HitGen = novel oral compounds for AD

Published on 07/06/2019

Almirall and HitGen entered in a multi-target research collaboration to develop novel oral chemical entities for patients suffering from moderate to severe atopic dermatitis

You are part of our success: AlmirallShare results

Published on 11/02/2019

More than 450 scientists subscribed and over 170 different proposals received

Digital + omics = unprecedented target-disease associations

Published on 23/01/2019

Partnership between Almirall, S.A. and Barcelona Supercomputing Center (BSC) to identify novel targets to treat dermatological diseases

SilicoDerm: new modeling techniques for dermatological research

Published on 31/10/2018

SilicoDerm computational methodologies will facilitate the identification of active compounds for the treatment of inflammatory skin diseases

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our policy of cookies, click on the link for more information.

Aviso de cookies